Protein Binding of Rifapentine and Its 25-Desacetyl Metabolite in Patients with Pulmonary Tuberculosis | Zendy

Eric F. Egelund | Zendy; Marc Weiner | Zendy; Rajendra Singh | Zendy; Thomas J. Prihoda | Zendy; Jonathon Gelfond | Zendy; Hartmut Derendorf | Zendy; William R. Mac Kenzie | Zendy; Charles A. Peloquin | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Protein Binding of Rifapentine and Its 25-Desacetyl Metabolite in Patients with Pulmonary Tuberculosis

Author(s) -

Eric F. Egelund,

Marc Weiner,

Rajendra Singh,

Thomas J. Prihoda,

Jonathon Gelfond,

Hartmut Derendorf,

William R. Mac Kenzie,

Charles A. Peloquin

Publication year - 2014

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.01730-13

Subject(s) - rifapentine , pharmacokinetics , tuberculosis , pharmacodynamics , pharmacology , free fraction , medicine , mycobacterium tuberculosis , latent tuberculosis , pathology

Rifapentine is highly protein bound in blood, but the free, unbound drug is the microbiologically active fraction. In this exploratory study, we characterized the free plasma fraction of rifapentine in 41 patients with tuberculosis. We found a lower total rifapentine concentration but significantly higher free rifapentine levels in African patients of black race compared to non-Africans. These data support larger pharmacokinetic/pharmacodynamic studies to confirm these findings and assess free rifapentine in relation to microbiological and clinical outcomes.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research